Turnstone Biologics Corp.
TSBX
$0.35
$0.0319.72%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | 9.03M | 14.42M | 644.00K | 15.79M | 11.60M |
| Gross Profit | -9.03M | -14.42M | -644.00K | -15.79M | -11.60M |
| SG&A Expenses | 3.22M | 3.94M | 4.33M | 4.90M | 4.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.25M | 18.37M | 22.06M | 20.69M | 16.00M |
| Operating Income | -12.25M | -18.37M | -22.06M | -20.69M | -16.00M |
| Income Before Tax | -12.04M | -17.85M | -21.30M | -19.61M | -16.62M |
| Income Tax Expenses | 835.00K | -816.00K | 2.00K | 16.00K | -165.00K |
| Earnings from Continuing Operations | -12.87M | -17.03M | -21.30M | -19.63M | -16.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.87M | -17.03M | -21.30M | -19.63M | -16.45M |
| EBIT | -12.25M | -18.37M | -22.06M | -20.69M | -16.00M |
| EBITDA | -11.91M | -17.88M | -21.56M | -20.18M | -15.34M |
| EPS Basic | -0.56 | -0.74 | -0.92 | -0.85 | -0.72 |
| Normalized Basic EPS | -0.35 | -0.48 | -0.58 | -0.53 | -0.40 |
| EPS Diluted | -0.56 | -0.74 | -0.92 | -0.85 | -0.72 |
| Normalized Diluted EPS | -0.35 | -0.48 | -0.58 | -0.53 | -0.40 |
| Average Basic Shares Outstanding | 23.06M | 23.04M | 23.04M | 23.01M | 22.93M |
| Average Diluted Shares Outstanding | 23.06M | 23.04M | 23.04M | 23.01M | 22.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |